<br>        Inclusion Criteria:<br><br>          1. Subjects who signed informed consent.<br><br>          2. Male subjects =18 and =79 years of age; female subjects =18 and =79 years of age of<br>             non-childbearing potential<br><br>          3. Weight within a BMI range of 19.0-35.0 kg/m2.<br><br>          4. CLCr according to Cockcroft Gault equation of:<br><br>               -  50-80 mL/min (mild renal impairment)<br><br>               -  30- <50 mL/min (moderate renal impairment)<br><br>               -  <30 mL/min (severe renal impairment)<br><br>               -  subjects receiving dialysis for =3 months before dosing (ESRD)<br><br>               -  >80 mL/min (normal renal function)<br><br>        Exclusion Criteria:<br><br>          1. Unwilling or unable to give informed consent.<br><br>          2. As a result of the medical screening process, the study physician considers the<br>             subject unfit for the study.<br><br>          3. Demonstrating excess in xanthine consumption (more than 5 cups of coffee or<br>             equivalent per day).<br><br>          4. Subjects who smoke more than 10 cigarettes a day.<br><br>          5. Subjects who consume more than 28 units (males) or more than 21 units (females) of<br>             alcohol per week.<br><br>          6. Any history of hypersensitivity to the IMP.<br><br>          7. For subjects with renal impairment: No clinically significant change in disease<br>             status within at least 1 month prior to study entry, as determined by the<br>             investigator.<br><br>          8. The subject had donated a unit of blood (450 mL) within the 3 months before dosing,<br>             or intends to donate in the month after the last scheduled visit.<br><br>          9. Participation in another clinical study with an investigational drug or device within<br>             the last month.<br><br>         10. Subjects with clinically significant telemetric ECG abnormalities on Day -1<br><br>         11. Significant allergies requiring intranasal or systemic corticosteroids during any<br>             time of the year or history of any anaphylactic reaction.<br><br>         12. Positive test for human immunodeficiency virus (HIV) antibodies.<br><br>         13. Acute Hepatitis B or C infection.<br><br>         14. The subject has tested positive for drugs of abuse at screening.<br><br>         15. Subjects who have received any prescribed systemic or topical medication within 4<br>             weeks prior to dosing (excluded are those drugs the renally impaired subject is<br>             currently taking for treatment of the renal or concomitant disease).<br><br>         16. Immunocompromised patients (patients after solid organ or bone marrow transplant;<br>             patients receiving immunosuppressive treatment).<br><br>         17. Subjects with known or suspected Pseudomonas infection or colonization (e.g. patients<br>             with cystic fibrosis).<br><br>         18. Subjects with significant liver function abnormalities<br><br>         19. Subjects with acute myocardial infection or unstable angina pectoris<br>